Exclusive Summary

• - Patent cliff unlocks access: core IP expired 2023–2025 across US/EU/JP, with multiple biosimilars approved or launching, enabling rapid multi-region entry.
• - Large and growing patient pools: psoriasis and IBD together exceed 100 million patients globally, with tens of millions eligible for systemic/biologic therapy.
• - 45 mg targets derm/rheum immediately: fits adult plaque psoriasis and PsA dosing; adding 90 mg and IV induction would unlock full IBD coverage.
• - Competition is intense but white spaces remain: early/tender opportunities persist in LATAM, SEA, MENA and parts of CEE/Africa.
• - Price plus compliance wins: China-based cost and capacity advantage, paired with CTD/GMP readiness, supports 30–60% discounts versus originator and faster registrations.